NCT07250217Recruiting
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Collection of Biological Samples for Research Purposes: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 13 Jan 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07250217
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 13 Jan 2026 to the primary completion date, 1 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment for AML other than hydroxyurea;
Other illness
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).
- Diagnosis of a hematologic disease other than AML;
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);
Other
- Patients deemed unsuitable for sampling by the surgeon performing the procedure;
- Patients under legal protection measures;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision;
- / AML Group
- Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;
- Severe comorbidities that could interfere with the study, as assessed by the principal investigator;
- Patients under legal protection;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision.
Who the study is looking for
- Age ≥ 60 years;
- Scheduled for cardiac surgery involving sternotomy;
- Normal blood count within the two months preceding sampling;
- Affiliated with, or beneficiary of, a social security system;
- Written informed consent to participate in the study.
- Age ≥ 60 years;
- Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;
- Affiliated with, or beneficiary of, a social security system;
- Written informed consent to participate in the study.
Criteria the registry did not label
- / Control Group
Age in the registry: 60 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Coordinator of this site? Confirm its status | Mulhouse | France | Recruiting |
| GHRMSA Coordinator of this site? Confirm its status | Mulhouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.